about
PEGylation of Interferon-β-1aDefining the clinical course of multiple sclerosis: the 2013 revisions.Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineAtacicept: targeting B cells in multiple sclerosisSubcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathiesOptimizing therapy early in multiple sclerosis: An evidence-based viewPredicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic NeuritisThe mechanism of action of interferon-β in relapsing multiple sclerosisDisease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responsesGuillain-Barré syndrome after exposure to influenza virusQuinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II moleculesPromoting myelination in an in vitro mouse model of the peripheral nervous system: the effect of wine ingredients [corrected]Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort AnalysisPurely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis.Acute disseminated encephalomyelitis: an update.No blocking effects of the pentapeptide QYNAD on Na+ channel subtypes expressed in Xenopus oocytes or action potential conduction in isolated rat sural nerve.PEG minocycline-liposomes ameliorate CNS autoimmune disease.Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.Defining a role for laquinimod in multiple sclerosis.Acute disseminated encephalomyelitis: an acute hit against the brain.Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity.Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-β in macrophages.Cladribine as a therapeutic option in multiple sclerosis.Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathyGlatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell deathPathogenesis and treatment of immune-mediated neuropathies.Chemotherapeutics in the treatment of multiple sclerosis.Tissue mRNA expression in rat of newly described matrix metalloproteinases.Immune-mediated neuropathies.Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.CD19 as a molecular target in CNS autoimmunity.Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b.Development of oral cladribine for the treatment of multiple sclerosis.Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.Immune mechanisms in chronic inflammatory demyelinating neuropathy.Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG oligonucleotideDisease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.
P50
Q22241420-459F52D4-7B25-4F4E-9B50-4222D1BBF58AQ22241654-CB1AE9D5-7B05-4D98-A7CE-8F9C44EC1F3BQ24597369-473D33AB-D995-457D-BDD0-40A144C84B60Q24628925-EC693502-EBCC-463B-8561-848FEB8D743AQ26745685-EE80F1ED-20BC-403C-B622-176ACE360DFAQ26783070-C402BA26-F917-48CE-87F8-FE44A7EA3C21Q27320796-D2A63F59-391A-4D63-8BB2-4AA81A3CC386Q28239752-B3DA02BC-7ADB-479E-A1F8-4C26027E66ADQ28289228-51328AAE-8535-4530-9897-B2FDBC114A2CQ28291850-973ABBB7-E524-430D-AF6E-CBE83B42C8A8Q28478607-AAF73507-B775-46EC-AF85-2437E3448C6EQ28533740-4E807812-2AED-4C10-BA14-04C09B43D613Q28553133-5C225D8C-7380-40F5-827A-634B08725F98Q31014036-2E388CF2-F8CA-41A4-B112-78D5EBB7D985Q31018411-C073235D-AD35-4571-8428-67241984CABBQ33195146-7F502AAB-EC25-40F1-A427-77F7DA91FF2FQ33398048-9E4A2AD9-9AAD-478D-85E5-F75AB94ACA95Q33589958-E199A98D-C58F-47EA-A80E-2C8D2DB028DAQ33847350-5E825C4A-5328-4EF6-B36C-30B6D8FCABEFQ34004095-9EBF5FB0-6FE4-4E91-855D-D277B9A1A82DQ34061505-7D1CDC19-6313-48E7-88BE-20309B597743Q34063671-E093410C-8676-4C54-8879-D075E88650CDQ34198064-7D33841F-B499-4C5D-AA3A-5381C5088ED1Q34324861-9F8D12CD-D70C-4BD6-8DC4-2FF8B7D49F89Q34358322-4A8DDE4E-49DB-473B-A1D8-DF15BE9DE04BQ34409385-E3F85630-0AF1-4081-B1B6-17B216433499Q34409536-8D5AFDD9-C874-4B56-AA20-4CE8AA5576FAQ34461365-88489EBC-B2A7-4297-8138-A48AD1DB38A7Q34573523-06ED6937-9880-4256-BF0C-1E35D1CD4D14Q34642592-C9B4738D-BA64-4504-9639-CBB5DAD6BB02Q34661731-95A76DC7-B7D4-421F-8806-2784C116E080Q34743580-AD0689FE-7E9C-4FD5-B09C-4CBDD5BC3572Q34976749-E5BEEB50-5479-45BB-A91C-729463D8B918Q34994463-7F4BABA4-0CFF-4EEC-9C08-2C5EE7706E8DQ35013390-67A38A4E-ED71-4ECB-9D76-384B60D07A5EQ35018491-2C7CD03F-A242-4489-90AE-C461C433AB26Q35030123-E6B4D691-CB32-4FB1-B10B-BFF6D9DE4B16Q35033516-E9FBEAE1-96E9-4D2A-8B30-307130B7B821Q35078163-96F76EC7-2350-4E43-B48D-FDFA4CA0AB39Q35094706-C6B1BF9E-D5FD-44AF-B5D6-A88DE1CCB5D5
P50
name
Bernd C Kieseier
@ast
Bernd C Kieseier
@en
Bernd C Kieseier
@nl
type
label
Bernd C Kieseier
@ast
Bernd C Kieseier
@en
Bernd C Kieseier
@nl
altLabel
B C Kieseier
@en
B Kieseier
@en
B. C. Kieseier
@en
B. Kieseier
@en
Bernd C. Kieseier
@en
Bernd Kieseier
@en
Kieseier B
@en
Kieseier B. C.
@en
Kieseier B.
@en
Kieseier BC
@en
prefLabel
Bernd C Kieseier
@ast
Bernd C Kieseier
@en
Bernd C Kieseier
@nl